opc 12759 has been researched along with Stomach Neoplasms in 26 studies
rebamipide: structure in first source; RN refers to (+-)-isomer; inhibits gastric xanthine oxidase
Stomach Neoplasms: Tumors or cancer of the STOMACH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this prospective, randomized, multicenter, open-label, and comparative study, patients who had undergone ESD for EGC or gastric adenoma were randomized into groups receiving either rabeprazole monotherapy (10 mg/day, n=64) or a combination of rabeprazole plus rebamipide (300 mg/day, n=66)." | 5.22 | Limited Effect of Rebamipide in Addition to Proton Pump Inhibitor (PPI) in the Treatment of Post-Endoscopic Submucosal Dissection Gastric Ulcers: A Randomized Controlled Trial Comparing PPI Plus Rebamipide Combination Therapy with PPI Monotherapy. ( Akahoshi, K; Akiho, H; Aso, A; Harada, N; Iboshi, Y; Ihara, E; Iwasa, T; Nakamura, K; Nakamura, N; Ochiai, T; Ogino, H; Takayanagi, R, 2016) |
| " No serious adverse events were observed in any of the patients in either group." | 2.80 | Efficacy and safety of 1-week Helicobacter pylori eradication therapy and 7-week rebamipide treatment after endoscopic submucosal dissection of early gastric cancer in comparison with 8-week PPI standard treatment: a randomized, controlled, prospective, m ( Azuma, T; Higuchi, K; Iguchi, M; Machida, H; Morita, Y; Naito, Y; Takeuchi, T; Takeuchi, Y; Tamada, T; Tominaga, K; Uedo, N; Yagi, N; Yamao, J; Yazumi, S, 2015) |
| "We examined 90 patients with early gastric cancer who had undergone ESD." | 2.78 | Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers. ( Asakuma, Y; Kashida, H; Kawasaki, M; Kudo, M; Matsui, S; Sakurai, T; Takayama, M, 2013) |
| " pylori, especially after MNU administration to promote carcinogenesis and the effects of the long-term administration of rebamipide or nimesulide were evaluated." | 2.42 | Chemoprevention of Helicobacter pylori-associated gastric carcinogenesis in a mouse model: is it possible? ( Cho, SW; Hahm, KB; Han, SU; Kim, DY; Kim, JH; Kim, MW; Kim, YB; Lee, JS; Nahm, KT; Oh, TY; Song, YJ; Surh, YJ; Yoo, BM, 2003) |
| "Improvement of gastritis is expressed not only in quantity but also in quality of gastritis, which is shown as the reduction of iNOS expression in the gastric mucosa." | 2.42 | Review article: clinical significance of mucosal-protective agents: acid, inflammation, carcinogenesis and rebamipide. ( Haruma, K; Ito, M, 2003) |
| "There were significant differences in gastric cancer incidence rates according to age, sex, and initial diagnosis at the time of index ESD." | 1.51 | Chemopreventive Effect of Rebamipide against Gastric Cancer in Patients who undergo Endoscopic Resection for Early Gastric Neoplasms: A Nationwide Claims Study. ( Lee, H; Seo, GH, 2019) |
| "MNNG-induced carcinogenesis and may also inhibit progression of cancer in rats." | 1.42 | Preventive effect of rebamipide on N-methyl-N'-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in rats. ( Ebi, M; Hayashi, N; Joh, T; Katano, T; Kataoka, H; Mizoshita, T; Mori, Y; Ozeki, K; Shimura, T; Tanida, S; Tatematsu, M; Tsukamoto, H; Tsukamoto, T, 2015) |
| "Its effect on gastric cancer cell growth and its regulatory mechanisms remain unknown." | 1.34 | Rebamipide inhibits gastric cancer cell growth. ( Arakawa, T; Pai, R; Tanigawa, T; Tarnawski, AS, 2007) |
| "We examined in human gastric cancer AGS cells: (1) survivin expression, (2) localization of survivin and Aurora-B, (3) cell proliferation, and (4) effects of specific survivin siRNA and/or rebamipide (free radical scavenging drug) on survivin and Aurora-B expression and cell proliferation." | 1.33 | Rebamipide inhibits gastric cancer growth by targeting survivin and Aurora-B. ( Chai, J; Chiou, SK; Chu, EC; Pai, R; Tarnawski, A, 2005) |
| "We have recently reported that a gastric cancer cell line, MKN45, produced a massive amount of IL-8 upon coculture with live H." | 1.30 | Molecular analysis of suppression of interleukin-8 production by rebamipide in Helicobacter pylori-stimulated gastric cancer cell lines. ( Aihara, M; Azuma, A; Funakoshi, Y; Imagawa, K; Kikuchi, M; Matsushima, K; Mukaida, N; Ohmoto, Y; Shindo, Y; Takizawa, H; Tsuchimoto, D, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.69) | 18.2507 |
| 2000's | 7 (26.92) | 29.6817 |
| 2010's | 15 (57.69) | 24.3611 |
| 2020's | 2 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Jung, DH | 1 |
| Park, JC | 1 |
| Lee, YC | 2 |
| Lee, SK | 1 |
| Shin, SK | 1 |
| Chung, H | 1 |
| Park, JJ | 1 |
| Kim, JH | 4 |
| Youn, YH | 1 |
| Park, H | 1 |
| Lee, JS | 2 |
| Jeon, SW | 1 |
| Lee, HS | 1 |
| Kwon, YH | 1 |
| Nam, SY | 1 |
| Bae, HI | 1 |
| Seo, AN | 1 |
| Ichida, T | 1 |
| Ueyama, S | 1 |
| Eto, T | 1 |
| Kusano, F | 1 |
| Sakai, Y | 2 |
| Seo, GH | 1 |
| Lee, H | 1 |
| Takayama, M | 1 |
| Matsui, S | 1 |
| Kawasaki, M | 1 |
| Asakuma, Y | 1 |
| Sakurai, T | 1 |
| Kashida, H | 1 |
| Kudo, M | 1 |
| Higuchi, K | 1 |
| Takeuchi, T | 1 |
| Uedo, N | 1 |
| Takeuchi, Y | 1 |
| Naito, Y | 2 |
| Yagi, N | 1 |
| Tominaga, K | 1 |
| Machida, H | 1 |
| Tamada, T | 1 |
| Morita, Y | 2 |
| Yazumi, S | 1 |
| Yamao, J | 1 |
| Iguchi, M | 1 |
| Azuma, T | 2 |
| Xiong, J | 1 |
| Lai, S | 1 |
| Zhang, P | 1 |
| Li, Q | 1 |
| Wei, Y | 1 |
| Yang, Y | 1 |
| Wang, T | 1 |
| Liu, L | 1 |
| Ma, X | 1 |
| Chen, D | 1 |
| Tsukamoto, H | 1 |
| Mizoshita, T | 1 |
| Katano, T | 1 |
| Hayashi, N | 1 |
| Ozeki, K | 1 |
| Ebi, M | 1 |
| Shimura, T | 1 |
| Mori, Y | 1 |
| Tanida, S | 1 |
| Kataoka, H | 1 |
| Tsukamoto, T | 1 |
| Tatematsu, M | 1 |
| Joh, T | 1 |
| Han, X | 1 |
| Jiang, K | 1 |
| Wang, B | 1 |
| Zhou, L | 1 |
| Chen, X | 1 |
| Li, S | 1 |
| Kang, DW | 3 |
| Noh, YN | 1 |
| Hwang, WC | 2 |
| Choi, KY | 2 |
| Min, do S | 2 |
| Nakamura, K | 1 |
| Ihara, E | 1 |
| Akiho, H | 1 |
| Akahoshi, K | 1 |
| Harada, N | 1 |
| Ochiai, T | 1 |
| Nakamura, N | 1 |
| Ogino, H | 1 |
| Iwasa, T | 1 |
| Aso, A | 1 |
| Iboshi, Y | 1 |
| Takayanagi, R | 1 |
| Min, G | 1 |
| Park, DY | 1 |
| Hong, KW | 1 |
| Fujiwara, S | 1 |
| Toyonaga, T | 1 |
| Kawakami, F | 1 |
| Itoh, T | 1 |
| Yoshida, M | 2 |
| Kutsumi, H | 1 |
| Kabeya, M | 1 |
| Ina, K | 1 |
| Yuasa, S | 1 |
| Kikuchi, F | 1 |
| Tajiri, C | 1 |
| Kato, T | 1 |
| Hibi, S | 1 |
| Minagawa, Y | 1 |
| Furuta, R | 1 |
| Kayukawa, S | 1 |
| Kataoka, T | 1 |
| Kawai, M | 1 |
| Kobayashi, M | 1 |
| Takeuchi, M | 1 |
| Hashimoto, S | 1 |
| Mizuno, K | 1 |
| Sato, Y | 1 |
| Narisawa, R | 1 |
| Aoyagi, Y | 1 |
| Shin, WG | 1 |
| Kim, SJ | 1 |
| Choi, MH | 1 |
| Kim, KO | 1 |
| Jang, HJ | 1 |
| Park, CH | 1 |
| Baek, IH | 1 |
| Kim, KH | 1 |
| Baik, GH | 1 |
| Kae, SH | 1 |
| Kim, HY | 1 |
| Park, MH | 1 |
| Ko, GH | 1 |
| Ha, WS | 1 |
| Kim, KS | 1 |
| Min, DS | 1 |
| Hahm, KB | 2 |
| Song, YJ | 1 |
| Oh, TY | 1 |
| Surh, YJ | 1 |
| Kim, YB | 1 |
| Yoo, BM | 1 |
| Han, SU | 1 |
| Nahm, KT | 1 |
| Kim, MW | 1 |
| Kim, DY | 1 |
| Cho, SW | 2 |
| Yoshida, N | 1 |
| Ishikawa, T | 1 |
| Ichiishi, E | 1 |
| Yoshida, Y | 1 |
| Hanashiro, K | 1 |
| Kuchide, M | 1 |
| Uchiyama, K | 1 |
| Kokura, S | 1 |
| Ichikawa, H | 1 |
| Yamamura, Y | 1 |
| Okanoue, T | 1 |
| Yoshikawa, T | 1 |
| Haruma, K | 1 |
| Ito, M | 1 |
| Shimada, S | 1 |
| Inoue, K | 1 |
| Kuramoto, M | 1 |
| Suzuki, S | 1 |
| Yamamoto, K | 1 |
| Ogawa, M | 1 |
| Tarnawski, A | 1 |
| Pai, R | 2 |
| Chiou, SK | 1 |
| Chai, J | 1 |
| Chu, EC | 1 |
| Tanigawa, T | 1 |
| Arakawa, T | 1 |
| Tarnawski, AS | 1 |
| Lee, KJ | 1 |
| Chung, MH | 1 |
| Aihara, M | 1 |
| Azuma, A | 1 |
| Takizawa, H | 1 |
| Tsuchimoto, D | 1 |
| Funakoshi, Y | 1 |
| Shindo, Y | 1 |
| Ohmoto, Y | 1 |
| Imagawa, K | 1 |
| Kikuchi, M | 1 |
| Mukaida, N | 1 |
| Matsushima, K | 1 |
| Masamune, A | 1 |
| Shimosegawa, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Is Rebamipide Effective on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection? : Multicenter, Randomized, and Prospective Study[NCT01167101] | 290 participants (Actual) | Interventional | 2009-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for opc 12759 and Stomach Neoplasms
| Article | Year |
|---|---|
Rebamipide plus proton pump inhibitor versus proton pump inhibitor alone in the treatment of endoscopic submucosal dissection-induced gastric ulcer: a meta-analysis of randomized controlled trials.
Topics: Adenoma; Aged; Aged, 80 and over; Alanine; Anti-Ulcer Agents; Drug Therapy, Combination; Endoscopy, | 2014 |
Chemoprevention of Helicobacter pylori-associated gastric carcinogenesis in a mouse model: is it possible?
Topics: Alanine; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cyto | 2003 |
Review article: clinical significance of mucosal-protective agents: acid, inflammation, carcinogenesis and rebamipide.
Topics: Alanine; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Anticarcinogenic Agents; Gastri | 2003 |
Helicobacter pylori infection, oxidative DNA damage, gastric carcinogenesis, and reversibility by rebamipide.
Topics: Alanine; Antioxidants; Apoptosis; DNA Damage; Helicobacter Infections; Helicobacter pylori; Humans; | 1998 |
12 trials available for opc 12759 and Stomach Neoplasms
| Article | Year |
|---|---|
Comparison of the Efficacy of Polaprezinc Plus Proton Pump Inhibitor and Rebamipide Plus Proton Pump Inhibitor Treatments for Endoscopic Submucosal Dissection-induced Ulcers.
Topics: Alanine; Anti-Ulcer Agents; Carnosine; Drug Therapy, Combination; Endoscopic Mucosal Resection; Huma | 2021 |
Rebamipide for the Improvement of Gastric Atrophy and Intestinal Metaplasia: A Prospective, Randomized, Pilot Study.
Topics: Alanine; Atrophy; Gastric Mucosa; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; | 2022 |
Randomized Controlled Trial Comparing the Effects of Vonoprazan Plus Rebamipide and Esomeprazole Plus Rebamipide on Gastric Ulcer Healing Induced by Endoscopic Submucosal Dissection.
Topics: Aged; Aged, 80 and over; Alanine; Anti-Ulcer Agents; Drug Therapy, Combination; Endoscopic Mucosal R | 2019 |
Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers.
Topics: Adenocarcinoma; Aged; Alanine; Anti-Ulcer Agents; Dissection; Female; Gastroscopy; Humans; Iatrogeni | 2013 |
Efficacy and safety of 1-week Helicobacter pylori eradication therapy and 7-week rebamipide treatment after endoscopic submucosal dissection of early gastric cancer in comparison with 8-week PPI standard treatment: a randomized, controlled, prospective, m
Topics: Aged; Alanine; Anti-Bacterial Agents; Clarithromycin; Dissection; Early Detection of Cancer; Female; | 2015 |
Effect of Rebamipide on the Premalignant Progression of Chronic Gastritis: A Randomized Controlled Study.
Topics: Alanine; CDX2 Transcription Factor; Disease Progression; Female; Gastric Mucosa; Gastritis; Helicoba | 2015 |
Limited Effect of Rebamipide in Addition to Proton Pump Inhibitor (PPI) in the Treatment of Post-Endoscopic Submucosal Dissection Gastric Ulcers: A Randomized Controlled Trial Comparing PPI Plus Rebamipide Combination Therapy with PPI Monotherapy.
Topics: Adenoma; Aged; Alanine; Anti-Ulcer Agents; Drug Therapy, Combination; Endoscopic Mucosal Resection; | 2016 |
A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Alanine; Anti-Ulcer Agents; Disease Progression; Drug | 2011 |
[Pilot study on clinical effects of rebamipide gargle against oral mucositis induced by fluoropyrimidines].
Topics: Alanine; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fluorouracil; Humans; Mouthwashes; Pilo | 2011 |
Contributing factors to gastric ulcer healing after endoscopic submucosal dissection including the promoting effect of rebamipide.
Topics: Aged; Aged, 80 and over; Alanine; Anti-Ulcer Agents; Drug Therapy, Combination; Endoscopy, Digestive | 2012 |
Can rebamipide and proton pump inhibitor combination therapy promote the healing of endoscopic submucosal dissection-induced ulcers? A randomized, prospective, multicenter study.
Topics: Adenoma; Aged; Alanine; Anti-Ulcer Agents; Carcinoma; Chi-Square Distribution; Confidence Intervals; | 2012 |
Preoperative administration of rebamipide significantly lowers body temperature and circulating interleukin-6 in gastric cancer patients after gastrectomy.
Topics: Aged; Alanine; Chemoprevention; Enzyme Inhibitors; Female; Fever; Gastrectomy; Humans; Interleukin-6 | 2003 |
10 other studies available for opc 12759 and Stomach Neoplasms
| Article | Year |
|---|---|
Chemopreventive Effect of Rebamipide against Gastric Cancer in Patients who undergo Endoscopic Resection for Early Gastric Neoplasms: A Nationwide Claims Study.
Topics: Administrative Claims, Healthcare; Aged; Alanine; Anti-Ulcer Agents; Dose-Response Relationship, Dru | 2019 |
Preventive effect of rebamipide on N-methyl-N'-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in rats.
Topics: Adenocarcinoma; Alanine; Animals; Antioxidants; Carcinogenesis; Carcinogens; Disease Models, Animal; | 2015 |
Rebamipide attenuates Helicobacter pylori CagA-induced self-renewal capacity via modulation of β-catenin signaling axis in gastric cancer-initiating cells.
Topics: Alanine; Animals; Anticarcinogenic Agents; Antigens, Bacterial; Apoptosis; Bacterial Proteins; beta | 2016 |
Rebamipide-induced downregulation of phospholipase D inhibits inflammation and proliferation in gastric cancer cells.
Topics: Alanine; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Gene Expression Regulation, Neoplast | 2010 |
Rebamipide abolishes Helicobacter pylori CagA-induced phospholipase D1 expression via inhibition of NFκB and suppresses invasion of gastric cancer cells.
Topics: Alanine; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Gene Expression Regulation, Enz | 2013 |
The effect of rebamipide on Helicobacter pylori extract-mediated changes of gene expression in gastric epithelial cells.
Topics: Alanine; Anti-Ulcer Agents; Chemokine CCL5; Chemokine CXCL2; Down-Regulation; Epithelial Cells; Fibr | 2003 |
Rebamipide inhibits gastric cancer growth by targeting survivin and Aurora-B.
Topics: Alanine; Aurora Kinase B; Aurora Kinases; Cell Line, Tumor; Cell Proliferation; Dose-Response Relati | 2005 |
Rebamipide inhibits gastric cancer cell growth.
Topics: Alanine; Anti-Ulcer Agents; Cell Proliferation; Cyclin-Dependent Kinases; Extracellular Signal-Regul | 2007 |
Molecular analysis of suppression of interleukin-8 production by rebamipide in Helicobacter pylori-stimulated gastric cancer cell lines.
Topics: Alanine; Anti-Ulcer Agents; Blotting, Northern; DNA Primers; Gene Expression Regulation, Neoplastic; | 1998 |
Rebamipide inhibits ceramide-induced interleukin-8 production in Kato III human gastric cancer cells.
Topics: Alanine; Anti-Ulcer Agents; Blotting, Northern; Blotting, Western; Ceramides; Enzyme Activation; Enz | 2001 |